Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Purchased by Barclays PLC

Barclays PLC increased its position in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 303.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 47,655 shares of the biopharmaceutical company’s stock after purchasing an additional 35,832 shares during the quarter. Barclays PLC’s holdings in Achieve Life Sciences were worth $226,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Achieve Life Sciences in the second quarter valued at approximately $482,000. Rhumbline Advisers purchased a new stake in Achieve Life Sciences in the 2nd quarter valued at $197,000. Renaissance Technologies LLC increased its stake in shares of Achieve Life Sciences by 134.2% in the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 14,360 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Achieve Life Sciences during the 2nd quarter worth $69,000. Finally, SG Americas Securities LLC acquired a new position in shares of Achieve Life Sciences during the 3rd quarter valued at about $54,000. 33.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ACHV. Raymond James began coverage on shares of Achieve Life Sciences in a research note on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 price target for the company. Rodman & Renshaw began coverage on Achieve Life Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, RODMAN&RENSHAW raised Achieve Life Sciences to a “strong-buy” rating in a research note on Thursday, November 14th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Achieve Life Sciences has an average rating of “Buy” and an average price target of $14.80.

Achieve Life Sciences Trading Down 4.1 %

ACHV opened at $3.55 on Tuesday. Achieve Life Sciences, Inc. has a 12 month low of $3.42 and a 12 month high of $5.59. The stock has a market capitalization of $122.08 million, a price-to-earnings ratio of -3.14 and a beta of 1.66. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. The business has a fifty day moving average price of $4.27 and a 200 day moving average price of $4.52.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same period in the previous year, the business earned ($0.34) earnings per share. Sell-side analysts expect that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.

Achieve Life Sciences Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.